You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 61 - 70 of 6715 results
  1. A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)

    SBC: Syntrix Biosystems, Inc.            Topic: 102

    Prostate cancer (PC) is the second leading cause of cancer-related death among American men, and the vast majority of these deaths are due to metastatic, castration-resistant PC (mCRPC). Androgen suppression therapy (AST) is used to treat PC patients, which comprise of: (1) androgen deprivation therapy (ADT) with LHRH agonists or antagonists; (2) blocking CYP17-mediated androgen synthesis with abi ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of multimode vacuum ionization for use in medical diagnostics

    SBC: MSTM LLC            Topic: NIAID

    There is a critical need for rapid and cost-effective means for the detection of e.g. infectious diseases at an early stage, drug overdoses, and other health related testing necessities. Thus, significant commercial opportunities exist because of the lack of these capabilities as painfully “demonstrated” in the current pandemic. Mass spectrometry (MS), because of its ability to detect hundreds ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Neutrophil Degranulation Inhibitor to Treat ARDS

    SBC: DEGRANIN THERAPEUTICS, LLC            Topic: NHLBI

    Project SummaryAcute respiratory distress syndrome (ARDS) is a critical problem in pulmonary medicine, accounting for 10% of intensive care unit (ICU) admissions and totaling over 200,000 patients/year in the U.S. Current treatment cost typically exceeds $70,000 per patient. Decades of clinical trials failed to identify effective pharmacologic therapy for ARDS, while mortality remains above 30%. T ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. VRSingTogether: Digital therapeutic virtual reality tool to mitigate the effects of Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD)

    SBC: RALPHVR INC            Topic: NIA

    Project Summary One in three seniors die with Alzheimer’s Disease (AD) or Alzheimer’s Disease related dementias (ADRD). More than six million Americans are living with AD and by 2050 this number is projected to rise to nearly 13 million. The economic costs of AD are significant, with 355 billion in national costs for caring for people with AD and ADRD. Disconcertingly, there is also an estimat ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Enabling standardized point-of-care tuberculosis diagnostics via rapid osmotic concentration

    SBC: TRULY TECHNOLOGIES LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Urine is an attractive biospecimen for point-of-care diagnostics because it can be collected in large quantities with noninvasive procedures. Urine-based lateral flow assays (LFAs) are low-cost devices suitable for point-of-care testing, particularly in low-resource settings. However, many urine-based LFAs exhibit sensitivity levels well below diagnostic utility due to the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. AI-based AML risk stratification using next generation cytogenomics

    SBC: PHASE GENOMICS, INC.            Topic: 394

    ABSTRACTChromosome aberrations are a hallmark of acute myeloid leukemia and offer mechanistic and prognostic insights into disease. As such, a combination of cytogenetic assays are routinely applied as a part of the AML diagnostic workflow. While offering invaluable information on disease severity, most chromosome aberrations fall into the “cytogenetic abnormalities not classified” or “compl ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A cross-species preclinical platform to enhance the translation of new medicines

    SBC: CURI BIO, INC.            Topic: 100

    PROJECT DESCRIPTION Duchenne muscular dystrophy (DMD) is a lethal, X-linked recessive disorder with no known cure that afflicts 1 in 5,000 newborn males. Patients carry a mutation in the dystrophin (DMD) gene, resulting in aberrant or absent expression of the dystrophin protein. Affected individuals experience progressive wasting of skeletal muscles and cardiac dysfunction leading to loss of ambul ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Emulsion digital PCR

    SBC: Dplexbio            Topic: NIAID

    Project Summary This proposed project aims to develop a new type of digital PCR platform which eliminates the need for uniform volumes and thereby reduces the complexity, cost, and run time of digital PCR while increasing its dynamic range. The result is a higher performance digital PCR system that matches the simplicity, speed, and low per-assay cost of real-time PCR. Real-time PCR maintains grea ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection

    SBC: VIRTICI LLC            Topic: NIAID

    Project Summary Our goal is to advance a novel, safe and effective sublingual (SL) vaccine against Neisseria gonorrhoeae (Ng) infection. Antibiotic resistant Ng is an interconnected global threat to people, animals, and the environment. Furthermore, approximately 50% of all annual Ng infections in the US are drug-resistant1. The emergence of drug-resistant Ng is accelerating, and previous antibiot ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Significant expansion of spectral multiplexing in PCR

    SBC: LAMPROGEN INC            Topic: 400

    Project Summary There have been long-standing discussions about the role of NGS (next-generation sequencing) versus real-time PCR in clinical diagnosis, prognosis, and screening. NGS offers unrivaled discovery power and represents the ultimate in multiplexing capability. NGS, however, is expensive and often requires complex workflows with a long turnaround time. Real-time PCR, in contrast, is comp ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government